​Cancer Res:这里有关于卵巢癌如何发展和演变的全新见解

2020-08-17 临床与基础研究

高度浆液性卵巢癌最常见的卵巢癌组织学亚型,占卵巢癌死亡人数的70-80%,并且与不良预后和频繁复发相关。 HGS卵巢癌是一种基因组复杂的疾病,其特征是普遍存在的TP53突变。

高度浆液性卵巢癌(HGSOC)是最常见的卵巢癌组织学亚型,占卵巢癌死亡人数的70-80%,并且与不良预后和频繁复发相关。 HGS卵巢癌是一种基因组复杂的疾病,其特征是普遍存在的TP53突变,由于基因断裂事件导致的RB1,NF1和PTEN频繁丢失以及反复出现的高水平拷贝数扩增。由于疾病的基因组复杂性和广泛的异质性,HGSOC的分子分层非常困难。目前,与临床相关的基因组分层仅限于鉴定同源重组缺陷(HRD),该疾病约占所有HGS卵巢肿瘤的一半,并且可归因于约20%HGSOC病例的种系或体细胞BRCA突变。

几项研究还通过将具有相似转录组谱的肿瘤聚集在一起,报道了分子上不同的亚型。癌症基因组图谱(TCGA)项目报告了四个亚型,并根据标记基因的表达将它们命名为:分化型,免疫反应型,间质性和增殖性。发现这些亚型与几种临床和肿瘤病理学特征有关,可能反映不同来源的组织,部分反映免疫细胞和基质含量的差异。转录组亚型的鲁棒性和临床实用性仍存在争议。基于由约1,800个HGSOC肿瘤组成的15个微阵列数据集的纲要,亚型分类器无法很好地适应独立的数据集,并且仅将三分之一的患者分为四个亚型。

大多数HGSOC肿瘤是多克隆的,这意味着单个肿瘤是不同亚型的不同癌症基因型的异质组装。据估计,TCGA HGSOC肿瘤中有95%是多克隆的,约40%的是由≥4个亚克隆组成的。最近的单细胞研究进一步表明,HGS卵巢肿瘤具有广泛的肿瘤内异质性,这与单个肿瘤是不同恶性细胞群的混合体的概念一致。

研究人员假设通过转录组聚类的亚型分配是由肿瘤进化中的晚期事件驱动的,因此这些亚型特性将是亚克隆特异性的。首先通过一种新型的等位基因特异性拷贝数的基因组区域被鉴定为散装肿瘤中的亚型标志物来检验这一假设。与基于多个时间点的纵向全基因组测序的系统发育分析相反,该方法从基因分型阵列或外显子组测序获得的拷贝数数据推断单个时间点的肿瘤进化。研究人员对六名独立患者进行单细胞RNA-seq(scRNA-seq)分析,研究单个上皮癌细胞是否具有不同的明确亚型,以及它们是否与建议的大肿瘤亚型相对应。

在美国,每年有20,000多名妇女接受新的卵巢癌诊断,每年约有14,000人死亡。本文对方法学和数十年的肿瘤发生过程有深刻的见解,具有基本的科学意义。这些见解对亚型靶向疗法的可行性具有帮助。在诊断之前了解异质性肿瘤的发展是困难的,因为我们无法直接观察到这种变化。但是,通过观察在该进化过程的不同阶段发现的肿瘤,并通过对肿瘤基因组学和异质性的详细研究,研究人员仍然可以学到一些东西。他们想知道的关键是,肿瘤是否会以某种亚型开始并以这种方式停留,还是随着时间的流逝而发展,变化,甚至繁殖。如果亚型可以在一个肿瘤内进化和繁殖,那么亚型特异性疗法就不太可能帮助。

多项研究已鉴定出高级浆液性卵巢癌(HGSOC)的转录组亚型,但尚未影响临床实践。HGSOC亚型的解释和翻译因肿瘤的进化和多克隆性以及体畸形的积累,不同细胞类型的混合物以及不同来源的组织而变得复杂。在这些因素的背景下,通过对癌症基因组图谱中的大量绝对体细胞拷贝数分析和基因表达的新型综合分析,以及对六个独立肿瘤的单细胞RNA-seq分析,对HGSOC亚型进化的时间顺序进行了检查。与软组织肉瘤相比,该方法得到了验证。与HGSOC亚型相关的基因组病变往往是亚克隆的,这意味着在肿瘤进化的后期亚型发散。HGSOC反复发作的亚克隆性在增生性肿瘤中尤为明显,其特征是极端的基因组不稳定,缺乏免疫浸润和患者年龄较大。相反,分化的肿瘤的特征是基因组完整,免疫渗透高,患者年龄年轻。研究人员提出了HGSOC离散亚型的替代模型,其中肿瘤沿着特征在于基因组不稳定性和亚克隆扩增增加的时间表从早期分化的频谱发展到晚期增殖的频谱。所提出的方法提供了一种通过多组学分析研究肿瘤演变的新方法。

这项研究提出了一种方法,以推断基于转录组的肿瘤组在癌变早期是否分化,因此可能是治疗的合适靶标,并证明高级别浆液性卵巢癌(HGSOC)并非如此。HGSOC的重要发现包括:可以从不同的基因组平台可靠地推断出肿瘤的纯度,倍性和亚克隆性,并显示亚型之间的显着差异。复发性DNA改变与亚型有关,并且倾向于在亚克隆中更频繁地发生对42,000个肿瘤细胞进行单细胞测序显示,肿瘤细胞类型组成中存在广泛的异质性,从而驱动大量亚型的调用,但表明肿瘤上皮细胞缺乏内在的亚型。

“我们使用互补但完全不同的方法来解决相同的问题-一种方法是使用更传统的方法,即对数百种大块肿瘤进行DNA和RNA测序,另一种方法是针对某些肿瘤,采用新的单细胞测序方法,” Waldron阐述道,“从这两种方法中看到一致的图景,确实增强了人们对来自两种新颖方法的结果的信心。”该研究的令人惊讶的结果是消除了该癌症的离散转录组亚型的想法,并用一种连续的肿瘤发展模型代替了该模型,该模型包括亚克隆的混合物,突变的积累,免疫和基质细胞以与肿瘤相关的比例浸润阶段和组织起源,以及先前与离散亚型相关的特性之间的进化。

在这项研究中,研究人员调查了基于基因表达的HGSOC亚型是否是由于单个肿瘤细胞水平上的固有歧义还是不同定义的亚型的亚克隆混合物所致。尽管与亚型相关的DNA改变倾向于在亚克隆中更频繁地发生,但研究人员发现这仅归因于增殖光谱肿瘤的总体更高的倍性和亚克隆性,而不是为存在具有不同明确亚型的亚克隆提供了证据。另一方面,对单个细胞的亚型分类表明,不同是由于以下因素的组合:(i)大量细胞类型的混合物,以及(ii)从一个亚型谱到另一个亚谱的特征。从这些观察中得出结论,离散亚型的概念实际上并不代表HGSOC的异质性和基因组复杂性。相反,研究人员提出HGSOC的特征是异质性,该异质性主要由肿瘤的演化和组成决定。在此模型中,肿瘤是由随机且个体不同的基因组改变(受一组受限制的进化运动引起的)从很大程度上完整的基因组(早期分化的光谱)发展为基因组完整性的全面丧失(后期增殖光谱),从而导致基因组的增加不稳定和亚克隆扩增。连同肿瘤纯度和组成的异质性,驱使肿瘤分配给免疫反应性和间充质谱,这为亚型分类的歧义提供了解释,其在细胞水平上也存在,甚至超过了大块肿瘤的分类歧义。使用人类样品对该模型进行实验验证将具有挑战性,因为随着肿瘤的发展从患者那里收集纵向样品是不可行的。纵向样品可以从发展自体卵巢癌的转基因小鼠获得。由于患者年龄与HGSOC的肿瘤分期之间存在密切关系,这也意味着较早的阶段可能至少部分是由于较早的发现,而不是更顽固的肿瘤,并且该阶段可能发展了数十年。随着在不久的将来可获得更多的用于HGSOC的单细胞数据,在治疗之前,期间和之后的关键过渡阶段,也将有可能更全面地研究肿瘤。

原始出处:

Ludwig Geistlinger, Sehyun Oh, Marcel Ramos,et al.Multi-omic analysis of subtype evolution and heterogeneity in high-grade serous ovarian carcinoma.Cancer Res. 2020 Aug 3;canres.0521.2020. doi: 10.1158/0008-5472.CAN-20-0521.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (10)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1745866, encodeId=176a1e4586661, content=<a href='/topic/show?id=34a5666451b' target=_blank style='color:#2F92EE;'>#演变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66645, encryptionId=34a5666451b, topicName=演变)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=96a135615295, createdName=oliver181, createdTime=Fri Mar 05 05:12:33 CST 2021, time=2021-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=811060, encodeId=0f6281106043, content=👍🏻, beContent=null, objectType=article, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=25e55411955, createdName=ms5000000741733160, createdTime=Wed Aug 19 16:25:46 CST 2020, time=2020-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=810951, encodeId=b6d08109515f, content=👍, beContent=null, objectType=article, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=25e55411955, createdName=ms5000000741733160, createdTime=Wed Aug 19 16:08:04 CST 2020, time=2020-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=810855, encodeId=97848108554e, content=👍, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=25e55411955, createdName=ms5000000741733160, createdTime=Wed Aug 19 15:57:42 CST 2020, time=2020-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=810854, encodeId=69d5810854d8, content=!, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=25e55411955, createdName=ms5000000741733160, createdTime=Wed Aug 19 15:57:40 CST 2020, time=2020-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=810004, encodeId=c01181000423, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=dfe85411515, createdName=ms8000001618437429, createdTime=Tue Aug 18 10:16:32 CST 2020, time=2020-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=809945, encodeId=833e8099457c, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b0105263028, createdName=14807c20m73暂无昵称, createdTime=Tue Aug 18 06:57:14 CST 2020, time=2020-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=809900, encodeId=6e6180990017, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fb682417917, createdName=1238d654m87暂无昵称, createdTime=Mon Aug 17 21:31:49 CST 2020, time=2020-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=809791, encodeId=fc3f809e9160, content=<a href='/topic/show?id=08f236865a8' target=_blank style='color:#2F92EE;'>#卵巢癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=143, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36865, encryptionId=08f236865a8, topicName=卵巢癌)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Mon Aug 17 19:29:53 CST 2020, time=2020-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=809737, encodeId=ecf5809e3721, content=积分, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e4745411518, createdName=lionet_z, createdTime=Mon Aug 17 17:13:31 CST 2020, time=2020-08-17, status=1, ipAttribution=)]
    2021-03-05 oliver181
  2. [GetPortalCommentsPageByObjectIdResponse(id=1745866, encodeId=176a1e4586661, content=<a href='/topic/show?id=34a5666451b' target=_blank style='color:#2F92EE;'>#演变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66645, encryptionId=34a5666451b, topicName=演变)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=96a135615295, createdName=oliver181, createdTime=Fri Mar 05 05:12:33 CST 2021, time=2021-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=811060, encodeId=0f6281106043, content=👍🏻, beContent=null, objectType=article, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=25e55411955, createdName=ms5000000741733160, createdTime=Wed Aug 19 16:25:46 CST 2020, time=2020-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=810951, encodeId=b6d08109515f, content=👍, beContent=null, objectType=article, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=25e55411955, createdName=ms5000000741733160, createdTime=Wed Aug 19 16:08:04 CST 2020, time=2020-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=810855, encodeId=97848108554e, content=👍, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=25e55411955, createdName=ms5000000741733160, createdTime=Wed Aug 19 15:57:42 CST 2020, time=2020-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=810854, encodeId=69d5810854d8, content=!, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=25e55411955, createdName=ms5000000741733160, createdTime=Wed Aug 19 15:57:40 CST 2020, time=2020-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=810004, encodeId=c01181000423, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=dfe85411515, createdName=ms8000001618437429, createdTime=Tue Aug 18 10:16:32 CST 2020, time=2020-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=809945, encodeId=833e8099457c, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b0105263028, createdName=14807c20m73暂无昵称, createdTime=Tue Aug 18 06:57:14 CST 2020, time=2020-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=809900, encodeId=6e6180990017, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fb682417917, createdName=1238d654m87暂无昵称, createdTime=Mon Aug 17 21:31:49 CST 2020, time=2020-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=809791, encodeId=fc3f809e9160, content=<a href='/topic/show?id=08f236865a8' target=_blank style='color:#2F92EE;'>#卵巢癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=143, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36865, encryptionId=08f236865a8, topicName=卵巢癌)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Mon Aug 17 19:29:53 CST 2020, time=2020-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=809737, encodeId=ecf5809e3721, content=积分, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e4745411518, createdName=lionet_z, createdTime=Mon Aug 17 17:13:31 CST 2020, time=2020-08-17, status=1, ipAttribution=)]
    2020-08-19 ms5000000741733160

    👍🏻

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1745866, encodeId=176a1e4586661, content=<a href='/topic/show?id=34a5666451b' target=_blank style='color:#2F92EE;'>#演变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66645, encryptionId=34a5666451b, topicName=演变)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=96a135615295, createdName=oliver181, createdTime=Fri Mar 05 05:12:33 CST 2021, time=2021-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=811060, encodeId=0f6281106043, content=👍🏻, beContent=null, objectType=article, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=25e55411955, createdName=ms5000000741733160, createdTime=Wed Aug 19 16:25:46 CST 2020, time=2020-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=810951, encodeId=b6d08109515f, content=👍, beContent=null, objectType=article, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=25e55411955, createdName=ms5000000741733160, createdTime=Wed Aug 19 16:08:04 CST 2020, time=2020-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=810855, encodeId=97848108554e, content=👍, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=25e55411955, createdName=ms5000000741733160, createdTime=Wed Aug 19 15:57:42 CST 2020, time=2020-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=810854, encodeId=69d5810854d8, content=!, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=25e55411955, createdName=ms5000000741733160, createdTime=Wed Aug 19 15:57:40 CST 2020, time=2020-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=810004, encodeId=c01181000423, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=dfe85411515, createdName=ms8000001618437429, createdTime=Tue Aug 18 10:16:32 CST 2020, time=2020-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=809945, encodeId=833e8099457c, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b0105263028, createdName=14807c20m73暂无昵称, createdTime=Tue Aug 18 06:57:14 CST 2020, time=2020-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=809900, encodeId=6e6180990017, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fb682417917, createdName=1238d654m87暂无昵称, createdTime=Mon Aug 17 21:31:49 CST 2020, time=2020-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=809791, encodeId=fc3f809e9160, content=<a href='/topic/show?id=08f236865a8' target=_blank style='color:#2F92EE;'>#卵巢癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=143, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36865, encryptionId=08f236865a8, topicName=卵巢癌)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Mon Aug 17 19:29:53 CST 2020, time=2020-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=809737, encodeId=ecf5809e3721, content=积分, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e4745411518, createdName=lionet_z, createdTime=Mon Aug 17 17:13:31 CST 2020, time=2020-08-17, status=1, ipAttribution=)]
    2020-08-19 ms5000000741733160

    👍

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1745866, encodeId=176a1e4586661, content=<a href='/topic/show?id=34a5666451b' target=_blank style='color:#2F92EE;'>#演变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66645, encryptionId=34a5666451b, topicName=演变)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=96a135615295, createdName=oliver181, createdTime=Fri Mar 05 05:12:33 CST 2021, time=2021-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=811060, encodeId=0f6281106043, content=👍🏻, beContent=null, objectType=article, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=25e55411955, createdName=ms5000000741733160, createdTime=Wed Aug 19 16:25:46 CST 2020, time=2020-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=810951, encodeId=b6d08109515f, content=👍, beContent=null, objectType=article, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=25e55411955, createdName=ms5000000741733160, createdTime=Wed Aug 19 16:08:04 CST 2020, time=2020-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=810855, encodeId=97848108554e, content=👍, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=25e55411955, createdName=ms5000000741733160, createdTime=Wed Aug 19 15:57:42 CST 2020, time=2020-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=810854, encodeId=69d5810854d8, content=!, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=25e55411955, createdName=ms5000000741733160, createdTime=Wed Aug 19 15:57:40 CST 2020, time=2020-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=810004, encodeId=c01181000423, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=dfe85411515, createdName=ms8000001618437429, createdTime=Tue Aug 18 10:16:32 CST 2020, time=2020-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=809945, encodeId=833e8099457c, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b0105263028, createdName=14807c20m73暂无昵称, createdTime=Tue Aug 18 06:57:14 CST 2020, time=2020-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=809900, encodeId=6e6180990017, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fb682417917, createdName=1238d654m87暂无昵称, createdTime=Mon Aug 17 21:31:49 CST 2020, time=2020-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=809791, encodeId=fc3f809e9160, content=<a href='/topic/show?id=08f236865a8' target=_blank style='color:#2F92EE;'>#卵巢癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=143, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36865, encryptionId=08f236865a8, topicName=卵巢癌)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Mon Aug 17 19:29:53 CST 2020, time=2020-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=809737, encodeId=ecf5809e3721, content=积分, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e4745411518, createdName=lionet_z, createdTime=Mon Aug 17 17:13:31 CST 2020, time=2020-08-17, status=1, ipAttribution=)]
    2020-08-19 ms5000000741733160

    👍

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1745866, encodeId=176a1e4586661, content=<a href='/topic/show?id=34a5666451b' target=_blank style='color:#2F92EE;'>#演变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66645, encryptionId=34a5666451b, topicName=演变)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=96a135615295, createdName=oliver181, createdTime=Fri Mar 05 05:12:33 CST 2021, time=2021-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=811060, encodeId=0f6281106043, content=👍🏻, beContent=null, objectType=article, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=25e55411955, createdName=ms5000000741733160, createdTime=Wed Aug 19 16:25:46 CST 2020, time=2020-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=810951, encodeId=b6d08109515f, content=👍, beContent=null, objectType=article, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=25e55411955, createdName=ms5000000741733160, createdTime=Wed Aug 19 16:08:04 CST 2020, time=2020-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=810855, encodeId=97848108554e, content=👍, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=25e55411955, createdName=ms5000000741733160, createdTime=Wed Aug 19 15:57:42 CST 2020, time=2020-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=810854, encodeId=69d5810854d8, content=!, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=25e55411955, createdName=ms5000000741733160, createdTime=Wed Aug 19 15:57:40 CST 2020, time=2020-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=810004, encodeId=c01181000423, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=dfe85411515, createdName=ms8000001618437429, createdTime=Tue Aug 18 10:16:32 CST 2020, time=2020-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=809945, encodeId=833e8099457c, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b0105263028, createdName=14807c20m73暂无昵称, createdTime=Tue Aug 18 06:57:14 CST 2020, time=2020-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=809900, encodeId=6e6180990017, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fb682417917, createdName=1238d654m87暂无昵称, createdTime=Mon Aug 17 21:31:49 CST 2020, time=2020-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=809791, encodeId=fc3f809e9160, content=<a href='/topic/show?id=08f236865a8' target=_blank style='color:#2F92EE;'>#卵巢癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=143, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36865, encryptionId=08f236865a8, topicName=卵巢癌)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Mon Aug 17 19:29:53 CST 2020, time=2020-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=809737, encodeId=ecf5809e3721, content=积分, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e4745411518, createdName=lionet_z, createdTime=Mon Aug 17 17:13:31 CST 2020, time=2020-08-17, status=1, ipAttribution=)]
    2020-08-19 ms5000000741733160

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1745866, encodeId=176a1e4586661, content=<a href='/topic/show?id=34a5666451b' target=_blank style='color:#2F92EE;'>#演变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66645, encryptionId=34a5666451b, topicName=演变)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=96a135615295, createdName=oliver181, createdTime=Fri Mar 05 05:12:33 CST 2021, time=2021-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=811060, encodeId=0f6281106043, content=👍🏻, beContent=null, objectType=article, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=25e55411955, createdName=ms5000000741733160, createdTime=Wed Aug 19 16:25:46 CST 2020, time=2020-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=810951, encodeId=b6d08109515f, content=👍, beContent=null, objectType=article, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=25e55411955, createdName=ms5000000741733160, createdTime=Wed Aug 19 16:08:04 CST 2020, time=2020-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=810855, encodeId=97848108554e, content=👍, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=25e55411955, createdName=ms5000000741733160, createdTime=Wed Aug 19 15:57:42 CST 2020, time=2020-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=810854, encodeId=69d5810854d8, content=!, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=25e55411955, createdName=ms5000000741733160, createdTime=Wed Aug 19 15:57:40 CST 2020, time=2020-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=810004, encodeId=c01181000423, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=dfe85411515, createdName=ms8000001618437429, createdTime=Tue Aug 18 10:16:32 CST 2020, time=2020-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=809945, encodeId=833e8099457c, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b0105263028, createdName=14807c20m73暂无昵称, createdTime=Tue Aug 18 06:57:14 CST 2020, time=2020-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=809900, encodeId=6e6180990017, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fb682417917, createdName=1238d654m87暂无昵称, createdTime=Mon Aug 17 21:31:49 CST 2020, time=2020-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=809791, encodeId=fc3f809e9160, content=<a href='/topic/show?id=08f236865a8' target=_blank style='color:#2F92EE;'>#卵巢癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=143, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36865, encryptionId=08f236865a8, topicName=卵巢癌)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Mon Aug 17 19:29:53 CST 2020, time=2020-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=809737, encodeId=ecf5809e3721, content=积分, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e4745411518, createdName=lionet_z, createdTime=Mon Aug 17 17:13:31 CST 2020, time=2020-08-17, status=1, ipAttribution=)]
    2020-08-18 ms8000001618437429

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1745866, encodeId=176a1e4586661, content=<a href='/topic/show?id=34a5666451b' target=_blank style='color:#2F92EE;'>#演变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66645, encryptionId=34a5666451b, topicName=演变)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=96a135615295, createdName=oliver181, createdTime=Fri Mar 05 05:12:33 CST 2021, time=2021-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=811060, encodeId=0f6281106043, content=👍🏻, beContent=null, objectType=article, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=25e55411955, createdName=ms5000000741733160, createdTime=Wed Aug 19 16:25:46 CST 2020, time=2020-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=810951, encodeId=b6d08109515f, content=👍, beContent=null, objectType=article, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=25e55411955, createdName=ms5000000741733160, createdTime=Wed Aug 19 16:08:04 CST 2020, time=2020-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=810855, encodeId=97848108554e, content=👍, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=25e55411955, createdName=ms5000000741733160, createdTime=Wed Aug 19 15:57:42 CST 2020, time=2020-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=810854, encodeId=69d5810854d8, content=!, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=25e55411955, createdName=ms5000000741733160, createdTime=Wed Aug 19 15:57:40 CST 2020, time=2020-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=810004, encodeId=c01181000423, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=dfe85411515, createdName=ms8000001618437429, createdTime=Tue Aug 18 10:16:32 CST 2020, time=2020-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=809945, encodeId=833e8099457c, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b0105263028, createdName=14807c20m73暂无昵称, createdTime=Tue Aug 18 06:57:14 CST 2020, time=2020-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=809900, encodeId=6e6180990017, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fb682417917, createdName=1238d654m87暂无昵称, createdTime=Mon Aug 17 21:31:49 CST 2020, time=2020-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=809791, encodeId=fc3f809e9160, content=<a href='/topic/show?id=08f236865a8' target=_blank style='color:#2F92EE;'>#卵巢癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=143, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36865, encryptionId=08f236865a8, topicName=卵巢癌)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Mon Aug 17 19:29:53 CST 2020, time=2020-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=809737, encodeId=ecf5809e3721, content=积分, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e4745411518, createdName=lionet_z, createdTime=Mon Aug 17 17:13:31 CST 2020, time=2020-08-17, status=1, ipAttribution=)]
    2020-08-18 14807c20m73暂无昵称

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=1745866, encodeId=176a1e4586661, content=<a href='/topic/show?id=34a5666451b' target=_blank style='color:#2F92EE;'>#演变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66645, encryptionId=34a5666451b, topicName=演变)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=96a135615295, createdName=oliver181, createdTime=Fri Mar 05 05:12:33 CST 2021, time=2021-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=811060, encodeId=0f6281106043, content=👍🏻, beContent=null, objectType=article, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=25e55411955, createdName=ms5000000741733160, createdTime=Wed Aug 19 16:25:46 CST 2020, time=2020-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=810951, encodeId=b6d08109515f, content=👍, beContent=null, objectType=article, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=25e55411955, createdName=ms5000000741733160, createdTime=Wed Aug 19 16:08:04 CST 2020, time=2020-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=810855, encodeId=97848108554e, content=👍, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=25e55411955, createdName=ms5000000741733160, createdTime=Wed Aug 19 15:57:42 CST 2020, time=2020-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=810854, encodeId=69d5810854d8, content=!, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=25e55411955, createdName=ms5000000741733160, createdTime=Wed Aug 19 15:57:40 CST 2020, time=2020-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=810004, encodeId=c01181000423, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=dfe85411515, createdName=ms8000001618437429, createdTime=Tue Aug 18 10:16:32 CST 2020, time=2020-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=809945, encodeId=833e8099457c, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b0105263028, createdName=14807c20m73暂无昵称, createdTime=Tue Aug 18 06:57:14 CST 2020, time=2020-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=809900, encodeId=6e6180990017, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fb682417917, createdName=1238d654m87暂无昵称, createdTime=Mon Aug 17 21:31:49 CST 2020, time=2020-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=809791, encodeId=fc3f809e9160, content=<a href='/topic/show?id=08f236865a8' target=_blank style='color:#2F92EE;'>#卵巢癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=143, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36865, encryptionId=08f236865a8, topicName=卵巢癌)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Mon Aug 17 19:29:53 CST 2020, time=2020-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=809737, encodeId=ecf5809e3721, content=积分, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e4745411518, createdName=lionet_z, createdTime=Mon Aug 17 17:13:31 CST 2020, time=2020-08-17, status=1, ipAttribution=)]
    2020-08-17 1238d654m87暂无昵称

    0

  9. [GetPortalCommentsPageByObjectIdResponse(id=1745866, encodeId=176a1e4586661, content=<a href='/topic/show?id=34a5666451b' target=_blank style='color:#2F92EE;'>#演变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66645, encryptionId=34a5666451b, topicName=演变)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=96a135615295, createdName=oliver181, createdTime=Fri Mar 05 05:12:33 CST 2021, time=2021-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=811060, encodeId=0f6281106043, content=👍🏻, beContent=null, objectType=article, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=25e55411955, createdName=ms5000000741733160, createdTime=Wed Aug 19 16:25:46 CST 2020, time=2020-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=810951, encodeId=b6d08109515f, content=👍, beContent=null, objectType=article, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=25e55411955, createdName=ms5000000741733160, createdTime=Wed Aug 19 16:08:04 CST 2020, time=2020-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=810855, encodeId=97848108554e, content=👍, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=25e55411955, createdName=ms5000000741733160, createdTime=Wed Aug 19 15:57:42 CST 2020, time=2020-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=810854, encodeId=69d5810854d8, content=!, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=25e55411955, createdName=ms5000000741733160, createdTime=Wed Aug 19 15:57:40 CST 2020, time=2020-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=810004, encodeId=c01181000423, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=dfe85411515, createdName=ms8000001618437429, createdTime=Tue Aug 18 10:16:32 CST 2020, time=2020-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=809945, encodeId=833e8099457c, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b0105263028, createdName=14807c20m73暂无昵称, createdTime=Tue Aug 18 06:57:14 CST 2020, time=2020-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=809900, encodeId=6e6180990017, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fb682417917, createdName=1238d654m87暂无昵称, createdTime=Mon Aug 17 21:31:49 CST 2020, time=2020-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=809791, encodeId=fc3f809e9160, content=<a href='/topic/show?id=08f236865a8' target=_blank style='color:#2F92EE;'>#卵巢癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=143, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36865, encryptionId=08f236865a8, topicName=卵巢癌)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Mon Aug 17 19:29:53 CST 2020, time=2020-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=809737, encodeId=ecf5809e3721, content=积分, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e4745411518, createdName=lionet_z, createdTime=Mon Aug 17 17:13:31 CST 2020, time=2020-08-17, status=1, ipAttribution=)]
  10. [GetPortalCommentsPageByObjectIdResponse(id=1745866, encodeId=176a1e4586661, content=<a href='/topic/show?id=34a5666451b' target=_blank style='color:#2F92EE;'>#演变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66645, encryptionId=34a5666451b, topicName=演变)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=96a135615295, createdName=oliver181, createdTime=Fri Mar 05 05:12:33 CST 2021, time=2021-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=811060, encodeId=0f6281106043, content=👍🏻, beContent=null, objectType=article, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=25e55411955, createdName=ms5000000741733160, createdTime=Wed Aug 19 16:25:46 CST 2020, time=2020-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=810951, encodeId=b6d08109515f, content=👍, beContent=null, objectType=article, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=25e55411955, createdName=ms5000000741733160, createdTime=Wed Aug 19 16:08:04 CST 2020, time=2020-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=810855, encodeId=97848108554e, content=👍, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=25e55411955, createdName=ms5000000741733160, createdTime=Wed Aug 19 15:57:42 CST 2020, time=2020-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=810854, encodeId=69d5810854d8, content=!, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=25e55411955, createdName=ms5000000741733160, createdTime=Wed Aug 19 15:57:40 CST 2020, time=2020-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=810004, encodeId=c01181000423, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=dfe85411515, createdName=ms8000001618437429, createdTime=Tue Aug 18 10:16:32 CST 2020, time=2020-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=809945, encodeId=833e8099457c, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b0105263028, createdName=14807c20m73暂无昵称, createdTime=Tue Aug 18 06:57:14 CST 2020, time=2020-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=809900, encodeId=6e6180990017, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fb682417917, createdName=1238d654m87暂无昵称, createdTime=Mon Aug 17 21:31:49 CST 2020, time=2020-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=809791, encodeId=fc3f809e9160, content=<a href='/topic/show?id=08f236865a8' target=_blank style='color:#2F92EE;'>#卵巢癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=143, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36865, encryptionId=08f236865a8, topicName=卵巢癌)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Mon Aug 17 19:29:53 CST 2020, time=2020-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=809737, encodeId=ecf5809e3721, content=积分, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e4745411518, createdName=lionet_z, createdTime=Mon Aug 17 17:13:31 CST 2020, time=2020-08-17, status=1, ipAttribution=)]
    2020-08-17 lionet_z

    积分

    0

相关资讯

药品评审中心(CDE)已受理Pamiparib治疗卵巢癌的新药申请

生物技术公司百济神州今日宣布,中国药品监督管理局(NMPA)的药品评审中心(CDE)已接受百济神州PARP1和PARP2研究性抑制剂Pamiparib的新药申请(NDA)。

Clin Cancer Res:WEE1激酶抑制剂adavosertib联合化疗治疗TP53突变型卵巢癌

临床前研究表明,WEE1激酶抑制剂adavosertib可使TP53突变细胞对化疗敏感。Oza等推测,adavosertib联合化疗可提高TP53突变的卵巢癌的疗效。

中国国家药品监督管理局将优先审查Pamiparib的新药申请

百济神州今日宣布,中国国家药品监督管理局(NMPA)药品评估中心(CDE)已授予Pamiparib新药审查优先权。

精准治疗时代,化疗仍是卵巢癌治疗的基石

卵巢癌是妇科常见的恶性肿瘤,在中国,其发病率仅次于宫颈癌和子宫内膜癌,致死率位居妇科生殖系统恶性肿瘤第二位,仅次于宫颈癌。据最新的中国癌症年报数据,每年新发病例大约5万例,死亡病例约23000例。

Clin cancer res:子宫内膜样卵巢癌或可采用子宫内膜癌的治疗策略

与其他卵巢癌相比,子宫内膜样卵巢癌(ENOC)的预后通常更好。尽管如此,目前的患者治疗仍然遵循“一刀切”的方法。即使肿瘤分期提供了分层,个性化的治疗仍然是难以实现的。

女性,腹痛半年,发热、呕吐1月,请诊断!

女性,腹痛半年,发热、呕吐1月,请诊断!